Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Moshit, Lindzen"'
Autor:
Arturo Simoni-Nieves, Moshit Lindzen, Suvendu Giri, Nitin Gupta, Rishita Chatterjee, Boobash-Raj Selvadurai, Marieke Van Daele, Danielle Love, Yuya Haga, Donatella Romaniello, Tomer-Meir Salame, Mirie Zerbib, Roni Oren, Yasuo Tsutsumi, Mattia Lauriola, Ilaria Marrocco, Yosef Yarden
Publikováno v:
Cell Reports Medicine, Vol 5, Iss 9, Pp 101703- (2024)
Summary: Activating EGFR (epidermal growth factor receptor) mutations can be inhibited by specific tyrosine kinase inhibitors (TKIs), which have changed the landscape of lung cancer therapy. However, due to secondary mutations and bypass receptors, s
Externí odkaz:
https://doaj.org/article/92b1210a06874d6d8474c3fe51ec1d80
Autor:
Kathrin Hedegger, Andreas Blutke, Theresa Hommel, Kerstin E. Auer, Nishanth B. Nataraj, Moshit Lindzen, Yosef Yarden, Maik Dahlhoff
Publikováno v:
Molecular Oncology, Vol 17, Iss 11, Pp 2415-2431 (2023)
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest of cancers. Attempts to develop targeted therapies still need to be established. Some oncogenic mechanisms in PDAC carcinogenesis harness the EGFR/ERBB receptor family. To explore the eff
Externí odkaz:
https://doaj.org/article/4848dd9e7e41435b882248abb977ac66
Autor:
Gretchen Bergado-Báez, Narjara Gonzalez Suarez, Lisset Chao García, Dayana Pérez-Martínez, Diana Rosa Hernández-Fernández, Talia Fundora-Barrios, Antonio Rodríguez-Álvarez, Geidy Diana Díaz-Ordaz, Moshit Lindzen, Yosef Yarden, Belinda Sánchez-Ramírez
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAntitumor therapies targeting HER1/EGFR and HER2, such as monoclonal antibodies (MAbs) and tyrosine-kinase inhibitors (TKIs), have demonstrated a significant clinical benefit, but the emergence of resistance limits long-term efficacy. While
Externí odkaz:
https://doaj.org/article/b6298bca5afe4fe9b20d85633b37935d
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
Autor:
Ilaria Marrocco, Donatella Romaniello, Itay Vaknin, Diana Drago‐Garcia, Roni Oren, Mary Luz Uribe, Nishanth Belugali Nataraj, Soma Ghosh, Raya Eilam, Tomer‐Meir Salame, Moshit Lindzen, Yosef Yarden
Publikováno v:
EMBO Molecular Medicine, Vol 13, Iss 4, Pp 1-18 (2021)
Abstract Some antibacterial therapies entail sequential treatments with different antibiotics, but whether this approach is optimal for anti‐cancer tyrosine kinase inhibitors (TKIs) remains open. EGFR mutations identify lung cancer patients who can
Externí odkaz:
https://doaj.org/article/f40e6d84396d426eb6294535a2d589ba
Autor:
Maicol Mancini, Hilah Gal, Nadège Gaborit, Luigi Mazzeo, Donatella Romaniello, Tomer Meir Salame, Moshit Lindzen, Georg Mahlknecht, Yehoshua Enuka, Dominick GA Burton, Lee Roth, Ashish Noronha, Ilaria Marrocco, Dan Adreka, Raya Eilam Altstadter, Emilie Bousquet, Julian Downward, Antonio Maraver, Valery Krizhanovsky, Yosef Yarden
Publikováno v:
EMBO Molecular Medicine, Vol 10, Iss 2, Pp 294-308 (2017)
Abstract Epidermal growth factor receptor (EGFR) mutations identify patients with lung cancer who derive benefit from kinase inhibitors. However, most patients eventually develop resistance, primarily due to the T790M second‐site mutation. Irrevers
Externí odkaz:
https://doaj.org/article/29209c6b4c714c0b85c5ff5816ce736b
Autor:
Yosef Yarden, Eytan Ruppin, Gad Getz, Aviv Regev, Joan S. Brugge, Rami I. Aqeilan, Trever G. Bivona, Laxmi Parida, Stefan Wiemann, Jideofor Ezike, Collin M. Blakely, Moshe Oren, Andrea Ardizzoni, Michelangelo Fiorentino, Mattia Lauriola, Brian P. Danysh, Diana Drago-Garcia, Youngmin Chung, Suvendu Giri, Arunachalam Sekar, Wei Wu, D. Lucas Kerr, Alexander Brandis, Sanju Sinha, Welles Robinson, Simone Borgoni, Rishita Chatterjee, Aakanksha Verma, Arturo Simoni-Nieves, Soma Ghosh, Rainer Will, Saptaparna Mukherjee, Moshit Lindzen, Sara Oster, Yaara Oren, Benny Zhitomirsky, Joo Sang Lee, Nishanth Belugali Nataraj, Ashish Noronha
Anticancer therapies have been limited by the emergence of mutations and other adaptations. In bacteria, antibiotics activate the SOS response, which mobilizes error-prone factors that allow for continuous replication at the cost of mutagenesis. We i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a90156dccca93cef0832f1138ce45eef
https://doi.org/10.1158/2159-8290.c.6549711
https://doi.org/10.1158/2159-8290.c.6549711
Autor:
Yosef Yarden, Eytan Ruppin, Gad Getz, Aviv Regev, Joan S. Brugge, Rami I. Aqeilan, Trever G. Bivona, Laxmi Parida, Stefan Wiemann, Jideofor Ezike, Collin M. Blakely, Moshe Oren, Andrea Ardizzoni, Michelangelo Fiorentino, Mattia Lauriola, Brian P. Danysh, Diana Drago-Garcia, Youngmin Chung, Suvendu Giri, Arunachalam Sekar, Wei Wu, D. Lucas Kerr, Alexander Brandis, Sanju Sinha, Welles Robinson, Simone Borgoni, Rishita Chatterjee, Aakanksha Verma, Arturo Simoni-Nieves, Soma Ghosh, Rainer Will, Saptaparna Mukherjee, Moshit Lindzen, Sara Oster, Yaara Oren, Benny Zhitomirsky, Joo Sang Lee, Nishanth Belugali Nataraj, Ashish Noronha
Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5b3d798497aa0ca157a505f562f91a6
https://doi.org/10.1158/2159-8290.22541643.v1
https://doi.org/10.1158/2159-8290.22541643.v1
Autor:
Yosef Yarden, Eytan Ruppin, Gad Getz, Aviv Regev, Joan S. Brugge, Rami I. Aqeilan, Trever G. Bivona, Laxmi Parida, Stefan Wiemann, Jideofor Ezike, Collin M. Blakely, Moshe Oren, Andrea Ardizzoni, Michelangelo Fiorentino, Mattia Lauriola, Brian P. Danysh, Diana Drago-Garcia, Youngmin Chung, Suvendu Giri, Arunachalam Sekar, Wei Wu, D. Lucas Kerr, Alexander Brandis, Sanju Sinha, Welles Robinson, Simone Borgoni, Rishita Chatterjee, Aakanksha Verma, Arturo Simoni-Nieves, Soma Ghosh, Rainer Will, Saptaparna Mukherjee, Moshit Lindzen, Sara Oster, Yaara Oren, Benny Zhitomirsky, Joo Sang Lee, Nishanth Belugali Nataraj, Ashish Noronha
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14e7bdbe0faeb9783a3dfad67e1dd091
https://doi.org/10.1158/2159-8290.22541646.v1
https://doi.org/10.1158/2159-8290.22541646.v1
Autor:
Yosef Yarden, Yasuo Tsutsumi, Stefan Wiemann, Suvendu Giri, Moshit Lindzen, Simone Borgoni, Diana Drago-Garcia, Arunachalam Sekar, Nishanth Belugali Nataraj, Mary Luz Uribe, Ashish Noronha, Ilaria Marrocco, Yuya Haga
Lung cancers driven by mutant forms of EGFR invariably develop resistance to kinase inhibitors, often due to secondary mutations. Here we describe an unconventional mechanism of resistance to dacomitinib, a newly approved covalent EGFR kinase inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35c2f22cb69147f185d8a21e6f9abc01
https://doi.org/10.1158/0008-5472.c.6513052.v1
https://doi.org/10.1158/0008-5472.c.6513052.v1
Autor:
Yosef Yarden, Yasuo Tsutsumi, Stefan Wiemann, Suvendu Giri, Moshit Lindzen, Simone Borgoni, Diana Drago-Garcia, Arunachalam Sekar, Nishanth Belugali Nataraj, Mary Luz Uribe, Ashish Noronha, Ilaria Marrocco, Yuya Haga
Supplementary Excel File 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70875629c5871ca720f2d40058f0a5cc
https://doi.org/10.1158/0008-5472.22428517.v1
https://doi.org/10.1158/0008-5472.22428517.v1